The test examines variants in GLP1R, GIPR, FTO, and MC4R genespolymorphisms that can influence appetite regulation, weight loss capacity, and individual dose requirements
Although the findings suggest that GLP-1 therapies may offer benefits beyond weight loss, liraglutide is the only GLP-1 receptor agonist evaluated in the clinic for migraine treatment
Panamas private clinics apply the same gold-standard assessment battery used at leading institutions in North America and Europe
Research also shows that gastrointestinal symptoms and other side effects are less likely to occur
Mean ratings (AUC 15300 min /285 min), maximum ratings and 15-min postprandial ratings were statistically significantly and similarly increased with liraglutide 1.8 and 3.0 mg compared with placebo for overall appetite score (indicating reduced appetite), satiety, fullness and 100-prospective food consumption (indicating reduced prospective consumption)